Cargando…
European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation
Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hamper...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498996/ https://www.ncbi.nlm.nih.gov/pubmed/37711401 http://dx.doi.org/10.3389/ti.2023.11358 |
_version_ | 1785105631634522112 |
---|---|
author | Berenguer, Marina de Martin, Eleonora Hessheimer, Amelia J. Levitsky, Josh Maluf, Daniel G. Mas, Valeria R. Selzner, Nazia Hernàndez-Èvole, Helena Lutu, Alina Wahid, Nabeel Zubair, Haseeb |
author_facet | Berenguer, Marina de Martin, Eleonora Hessheimer, Amelia J. Levitsky, Josh Maluf, Daniel G. Mas, Valeria R. Selzner, Nazia Hernàndez-Èvole, Helena Lutu, Alina Wahid, Nabeel Zubair, Haseeb |
author_sort | Berenguer, Marina |
collection | PubMed |
description | Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article. |
format | Online Article Text |
id | pubmed-10498996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104989962023-09-14 European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation Berenguer, Marina de Martin, Eleonora Hessheimer, Amelia J. Levitsky, Josh Maluf, Daniel G. Mas, Valeria R. Selzner, Nazia Hernàndez-Èvole, Helena Lutu, Alina Wahid, Nabeel Zubair, Haseeb Transpl Int Health Archive Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article. Frontiers Media S.A. 2023-08-30 /pmc/articles/PMC10498996/ /pubmed/37711401 http://dx.doi.org/10.3389/ti.2023.11358 Text en Copyright © 2023 Berenguer, de Martin, Hessheimer, Levitsky, Maluf, Mas, Selzner, Hernàndez-Èvole, Lutu, Wahid and Zubair. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Health Archive Berenguer, Marina de Martin, Eleonora Hessheimer, Amelia J. Levitsky, Josh Maluf, Daniel G. Mas, Valeria R. Selzner, Nazia Hernàndez-Èvole, Helena Lutu, Alina Wahid, Nabeel Zubair, Haseeb European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation |
title | European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation |
title_full | European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation |
title_fullStr | European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation |
title_full_unstemmed | European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation |
title_short | European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation |
title_sort | european society for organ transplantation consensus statement on biomarkers in liver transplantation |
topic | Health Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498996/ https://www.ncbi.nlm.nih.gov/pubmed/37711401 http://dx.doi.org/10.3389/ti.2023.11358 |
work_keys_str_mv | AT berenguermarina europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT demartineleonora europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT hessheimerameliaj europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT levitskyjosh europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT malufdanielg europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT masvaleriar europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT selznernazia europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT hernandezevolehelena europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT lutualina europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT wahidnabeel europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation AT zubairhaseeb europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation |